Eisai revises indicated uses for Neuzym medication
Eisai officials recently announced that the drug would undergo a partial label change to remove chronic sinusitis from the list of approved indications. A re-evaluation of the drug began in 2012, when double-blind, placebo-controlled studies showed Neuzym's effectiveness for the treatment of chronic sinusitis could not be verified.
It is still indicated for use to treat bronchitis, bronchial asthma and bronchiectasis; however, testing is ongoing, and additional label changes may occur.
Eisai is based in Tokyo, Japan. Neuzym's uses were approved by the Japanese Ministry of Health. There are six Neuzym products on the market: Neuzym Tablets, Neuzym Granules, Neuzym Fine Granules and Neuzym Syrup. All are manufactured by Sannova, Eisai's pharmaceutical subsidiary.
Organizations in this story
Eisai 100 Tice Blvd. Woodcliff Lake, NJ 07677